Didem Ardıçlı

Didem Ardıçlı

Auto-generated profile, based on publicly available information

Didem Ardıçlı

Ankara Bilkent City Hospital, Department of Pediatric Neurology, Ankara, TR, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2019 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
RSRosanne Sprute
Rosanne Sprute
DADidem Ardicli
Didem Ardicli
KOKader Karli Oguz
Kader Karli Oguz
AMAnna Malenica-Mandel
Anna Malenica-Mandel
HDHülya-Sevcan Daimagüler
Hülya-Sevcan Daimagüler
SCSebahattin Cirak
Sebahattin Cirak
Asparagine synthetase deficiency (ASNSD, OMIM #615574) is a rare autosomal recessive neurometabolic inborn error that leads to severe cognitive impairment. It manifests with microcephaly, intractable seizures, and progressive cerebral atrophy. Currently, there is no established treatment for this condition. In our pediatric cohort, we discovered, by whole-exome sequencing in two siblings from Turkey, a novel homozygous missense mutation in asparagine synthetase at NM_133436.3 (ASNS_v001): c.1108C>T that results in an amino acid exchange p.(Leu370Phe), in the C-terminal domain. After identification of the metabolic defect, treatment with oral asparagine supplementation was attempted in both patients for 24 months. Asparagine supplementation was well tolerated, and no further disease progression was observed during treatment. One of our patients showed mild developmental progress with increased levels of attention and improved nonverbal communication. These results support our hypothesis that asparagine supplementation should be further investigated as a treatment option for ASNSD. We further reviewed all previously reported ASNSD cases with regard for their clinical phenotypes and brain imaging findings to provide an essential knowledge base for rapid diagnosis and future clinical studies.

1 July 2021 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
DADidem Ardicli
Didem Ardicli
GHGoknur Haliloglu
Goknur Haliloglu
RGRahsan Gocmen
Rahsan Gocmen
CGCeren Gunbey
Ceren Gunbey
MTMeral Topcu
Meral Topcu

15 February 2024 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
YYYILMAZ YILDIZ
YILMAZ YILDIZ
DADidem Ardıçlı
Didem Ardıçlı
RGRahşan Göçmen
Rahşan Göçmen
DYDilek Yalnızoğlu
Dilek Yalnızoğlu
MTMeral Topçu
Meral Topçu
GHGöknur Haliloğlu
Göknur Haliloğlu

5 February 2026 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
HKHilal Karpuzcu
Hilal Karpuzcu
FKFatih Mehmet Kışlal
Fatih Mehmet Kışlal
DADidem Ardıçlı
Didem Ardıçlı
DYDeniz Yılmaz
Deniz Yılmaz

23 August 2019 in Journal of Nutrition and Dietetics
Verified
Journal Article
Open access
PDF file
FIFatma Ilgaz
Fatma Ilgaz
CGCeren Günbey
Ceren Günbey
DADidem Ardıçlı
Didem Ardıçlı
DYDilek Yalnızoğlu
Dilek Yalnızoğlu
MTMeral Topçu
Meral Topçu
Yüksek oranda yağ, yeterli miktarda protein ve düşük karbonhidrat içeren ve açlıkta olduğu gibi vücudu glukoz yerine başlıca yağlardan enerji sağlayacak şekilde yönlendiren ketojenik diyet, geçmişten günümüze ilaca dirençli epilepsi hastalarının tedavisinde ilk akla gelen tedavi seçeneğidir. İlk olarak 1920’li yılların başında ‘klasik ketojenik diyet’ ile başlayan geleneksel KD tedavisini, diyetin yeni etki mekanizmalarının keşfedilmesi ile birlikte 2000’li yılların başından itibaren ortaya çıkan ve daha az kısıtlama yapılan alternatif KD’ler izlemiştir. Alternatif diyetler çoğunlukla diyete uyumun azaldığı adölesan (12-18 yaş) dönemde tercih edilse de, ciddi davranış sorunları olan ve diyetten fayda görmesine rağmen diyete uyumun azalması nedeniyle nöbet kontrolü sağlanamayan daha küçük yaştaki çocuklarda da göz önünde bulundurulması gerekebilir. Bu alternatif KD’lerden birisi olan düşük glisemik indeks tedavisi (LGIT) kan glukoz düzeylerini minimal ve stabil düzeyde tutmayı amaçlar ve bu şekilde epileptik nöbetler kontrol altına alınır. LGIT, klasik KD’e oranla daha fazla karbonhidrat (enerjinin yaklaşık %10’u, günde 40-60 g/gün düşük glisemik indeksli karbonhidratlar) ve protein (enerjinin %25’i) alımına, dolayısı ile daha fazla besin tüketimine olanak sağlar. Bu olgu sunumunda, preadölesan dönemde olan ve hafif nöbet bulguları, şiddetli elektroansefalogram (EEG) bozukluğu ve davranış bozuklukları ile izlenen bir vakada, klasik KD uygulamasındaki zorluklar ve LGIT diyetine geçişin tedavinin etkinliği üzerindeki etkileri tartışılmıştır.

2 October 2024 in Paediatrics and International Child Health
Verified
Journal Article
Closed access
MPMerve Cansu Polat
Merve Cansu Polat
MAMeryem Hilal Altaş
Meryem Hilal Altaş
AAAlkim Oden Akman
Alkim Oden Akman
ATAli Kansu Tehçi
Ali Kansu Tehçi
DADidem Ardıçlı
Didem Ardıçlı
VGVildan Güngörer
Vildan Güngörer
Juvenile dermatomyositis (JDM) is an auto-immune disease characterised by muscle weakness and typical skin findings. Although peri-orbital oedema and facial swelling are compatible cutaneous findings in JDM, they are extremely rare. A 7-year-old boy who presented with peri-orbital oedema and facial swelling without muscle weakness is reported. In addition, he had cholestasis and marked cytopenia, which are uncommon in JDM, and malignancy and metabolic disorders were primarily considered in the aetiology. He had no musculoskeletal complaints other than elevated muscle enzymes on presentation but developed muscle weakness during follow-up, and a muscle biopsy was compatible with inflammatory myopathy. He responded favourably to conventional treatment and there were no physical limitations or skin findings by the 14th month of follow-up. Although patients presenting with typical clinical features are easy to diagnose, atypical skin findings are challenging for the clinician. In the presence of atypical skin and clinical findings in addition to muscle enzyme elevation, JDM should be considered in the differential diagnosis.Abbreviations: AHCE: asymptomatic hyper-CKemia; AST: aspartate aminotransferase; C: complement; CK: creatine kinase; IVIG: intravenous immunoglobulin; IIM: idiopathic inflammatory myopathy; JDM: juvenile dermatomyositis; LDH: lactate dehydrogenase; MAA: myositis-associated antibodies; MDA5: melanoma differentiation-associated gene 5; MRC: Medical Research Council; MRI: magnetic resonance imaging; MSA: myositis-specific antibodies; MTX: methotrexate NXP2: nuclear matrix protein 2; STIR: short tau inversion recovery; US: ultrasound.